D.E. Shaw & Co
VTVT icon

D.E. Shaw & Co’s vTv Therapeutics VTVT Stock Holding History

D.E. Shaw & Co’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,540
Closed -$414K – 5265
2021
Q2 		$414K Buy
+4,540
New +$460K ﹤0.01% 4124
2020
Q1 		– Sell
-517
Closed -$35K – 4296
2019
Q4 		$35K Sell
517
-223
-30% -$13.5K ﹤0.01% 3906
2019
Q3 		$46K Sell
740
-1,148
-61% -$64.8K ﹤0.01% 3731
2019
Q2 		$108K Sell
1,888
-357
-16% -$21.4K ﹤0.01% 3540
2019
Q1 		$154K Buy
2,245
+487
+28% +$47.2K ﹤0.01% 3435
2018
Q4 		$186K Buy
+1,758
New +$163K ﹤0.01% 3561

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAG
Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

D.E. Shaw & Co's VTVT Position: Q3 2021 in Review

D.E. Shaw & Co sold out of vTv Therapeutics (VTVT) in Q3 2021, closing a stake of 4,540 shares — an estimated $414K sold.

D.E. Shaw & Co first reported a position in VTVT in Q4 2018 and held it in 6 quarters. The position peaked at $414K in Q2 2021. 31 funds tracked by Wall St. Rank hold VTVT as of Q3 2021.

  • D.E. Shaw & Co reported no remaining vTv Therapeutics position as of Q3 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 4,540 vTv Therapeutics shares in Q3 2021, an estimated $414K.
  • D.E. Shaw & Co first reported a position in vTv Therapeutics in Q4 2018 and held it in 6 quarters.
  • D.E. Shaw & Co's vTv Therapeutics position peaked at $414K in Q2 2021.
  • 31 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.